Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $38.5 million.

  • CG Oncology's Total Non-Current Liabilities changed N/A to $38.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.5 million, marking a year-over-year change of. This contributed to the annual value of $21.4 million for FY2024, which is 5142.09% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Total Non-Current Liabilities is $38.5 million.
  • In the past 5 years, CG Oncology's Total Non-Current Liabilities ranged from a high of $38.5 million in Q3 2025 and a low of $14.1 million during Q4 2023
  • For the 3-year period, CG Oncology's Total Non-Current Liabilities averaged around $24.7 million, with its median value being $21.4 million (2024).
  • Data for CG Oncology's Total Non-Current Liabilities shows a peak YoY increase of 5142.09% (in 2024) and a maximum YoY decrease of 5142.09% (in 2024) over the last 5 years.
  • Over the past 3 years, CG Oncology's Total Non-Current Liabilities (Quarter) stood at $14.1 million in 2023, then soared by 51.42% to $21.4 million in 2024, then surged by 79.58% to $38.5 million in 2025.
  • Its Total Non-Current Liabilities stands at $38.5 million for Q3 2025, versus $21.4 million for Q4 2024 and $14.1 million for Q4 2023.